vs
Side-by-side financial comparison of Sanara MedTech Inc. (SMTI) and WEST BANCORPORATION INC (WTBA). Click either name above to swap in a different company.
Sanara MedTech Inc. is the larger business by last-quarter revenue ($27.5M vs $26.9M, roughly 1.0× WEST BANCORPORATION INC). WEST BANCORPORATION INC runs the higher net margin — 39.2% vs -5.9%, a 45.1% gap on every dollar of revenue. On growth, WEST BANCORPORATION INC posted the faster year-over-year revenue change (16.6% vs 4.6%). WEST BANCORPORATION INC produced more free cash flow last quarter ($12.4M vs $3.9M). Over the past eight quarters, Sanara MedTech Inc.'s revenue compounded faster (21.8% CAGR vs 17.3%).
Sanara MedTech Inc. is a US-based medical technology company that develops, manufactures, and distributes innovative surgical, wound care, and post-acute rehabilitation products. It mainly serves healthcare providers, hospitals, and long-term care facilities across North America, with a portfolio of FDA-cleared solutions designed to improve patient outcomes and lower clinical care operational costs.
West Bancorporation Inc. is a regional financial holding company headquartered in the U.S. Midwest, primarily serving markets across Iowa and Minnesota. It provides a full suite of personal and commercial banking services, including deposit accounts, mortgage loans, business lending, and wealth management solutions for individual consumers, small-to-medium enterprises, and local organizational clients.
SMTI vs WTBA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $27.5M | $26.9M |
| Net Profit | $-1.6M | $10.6M |
| Gross Margin | 93.2% | — |
| Operating Margin | 23.5% | 50.0% |
| Net Margin | -5.9% | 39.2% |
| Revenue YoY | 4.6% | 16.6% |
| Net Profit YoY | 5.3% | 34.8% |
| EPS (diluted) | $-0.32 | $0.61 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $26.9M | ||
| Q4 25 | $27.5M | $24.2M | ||
| Q3 25 | $26.3M | $25.0M | ||
| Q2 25 | $25.8M | $23.8M | ||
| Q1 25 | $23.4M | $23.1M | ||
| Q4 24 | $26.3M | $20.9M | ||
| Q3 24 | $21.7M | $20.3M | ||
| Q2 24 | $20.2M | $19.6M |
| Q1 26 | — | $10.6M | ||
| Q4 25 | $-1.6M | $7.4M | ||
| Q3 25 | $-30.4M | $9.3M | ||
| Q2 25 | $-2.0M | $8.0M | ||
| Q1 25 | $-3.5M | $7.8M | ||
| Q4 24 | $-1.7M | $7.1M | ||
| Q3 24 | $-2.9M | $6.0M | ||
| Q2 24 | $-3.5M | $5.2M |
| Q1 26 | — | — | ||
| Q4 25 | 93.2% | — | ||
| Q3 25 | 92.9% | — | ||
| Q2 25 | 92.5% | — | ||
| Q1 25 | 92.2% | — | ||
| Q4 24 | 91.4% | — | ||
| Q3 24 | 90.8% | — | ||
| Q2 24 | 90.0% | — |
| Q1 26 | — | 50.0% | ||
| Q4 25 | 23.5% | 39.6% | ||
| Q3 25 | 11.2% | 45.8% | ||
| Q2 25 | -0.1% | 43.4% | ||
| Q1 25 | -8.9% | 43.4% | ||
| Q4 24 | 18.6% | 30.9% | ||
| Q3 24 | 3.6% | 36.6% | ||
| Q2 24 | -14.3% | 32.6% |
| Q1 26 | — | 39.2% | ||
| Q4 25 | -5.9% | 30.7% | ||
| Q3 25 | -115.5% | 37.3% | ||
| Q2 25 | -7.8% | 33.5% | ||
| Q1 25 | -15.1% | 34.0% | ||
| Q4 24 | -6.5% | 34.0% | ||
| Q3 24 | -13.2% | 29.3% | ||
| Q2 24 | -17.4% | 26.5% |
| Q1 26 | — | $0.61 | ||
| Q4 25 | $-0.32 | $0.44 | ||
| Q3 25 | $-3.40 | $0.55 | ||
| Q2 25 | $-0.23 | $0.47 | ||
| Q1 25 | $-0.41 | $0.46 | ||
| Q4 24 | $-0.18 | $0.41 | ||
| Q3 24 | $-0.34 | $0.35 | ||
| Q2 24 | $-0.41 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $16.6M | $362.0M |
| Total DebtLower is stronger | $46.0M | — |
| Stockholders' EquityBook value | $5.9M | $270.7M |
| Total Assets | $72.9M | $4.0B |
| Debt / EquityLower = less leverage | 7.74× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $362.0M | ||
| Q4 25 | $16.6M | $471.1M | ||
| Q3 25 | $14.9M | $232.9M | ||
| Q2 25 | $17.0M | $345.2M | ||
| Q1 25 | $20.7M | — | ||
| Q4 24 | $15.9M | $243.5M | ||
| Q3 24 | $16.3M | — | ||
| Q2 24 | $6.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | $46.0M | — | ||
| Q3 25 | $45.1M | — | ||
| Q2 25 | $44.2M | — | ||
| Q1 25 | $43.4M | — | ||
| Q4 24 | $30.7M | — | ||
| Q3 24 | $30.1M | — | ||
| Q2 24 | $14.4M | — |
| Q1 26 | — | $270.7M | ||
| Q4 25 | $5.9M | $266.0M | ||
| Q3 25 | $6.1M | $255.1M | ||
| Q2 25 | $35.4M | $240.9M | ||
| Q1 25 | $36.7M | $237.9M | ||
| Q4 24 | $39.4M | $227.9M | ||
| Q3 24 | $39.8M | $235.4M | ||
| Q2 24 | $41.7M | $223.9M |
| Q1 26 | — | $4.0B | ||
| Q4 25 | $72.9M | $4.1B | ||
| Q3 25 | $71.1M | $4.0B | ||
| Q2 25 | $98.8M | $4.1B | ||
| Q1 25 | $96.4M | $4.0B | ||
| Q4 24 | $88.1M | $4.0B | ||
| Q3 24 | $88.5M | $4.0B | ||
| Q2 24 | $73.4M | $4.0B |
| Q1 26 | — | — | ||
| Q4 25 | 7.74× | — | ||
| Q3 25 | 7.33× | — | ||
| Q2 25 | 1.25× | — | ||
| Q1 25 | 1.18× | — | ||
| Q4 24 | 0.78× | — | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | 0.34× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.9M | $12.9M |
| Free Cash FlowOCF − Capex | $3.9M | $12.4M |
| FCF MarginFCF / Revenue | 14.0% | 46.0% |
| Capex IntensityCapex / Revenue | 0.3% | 1.8% |
| Cash ConversionOCF / Net Profit | — | 1.22× |
| TTM Free Cash FlowTrailing 4 quarters | $2.2M | $79.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $12.9M | ||
| Q4 25 | $3.9M | $46.5M | ||
| Q3 25 | $2.2M | $11.4M | ||
| Q2 25 | $2.7M | $13.5M | ||
| Q1 25 | $-2.0M | $9.7M | ||
| Q4 24 | $932.0K | $39.8M | ||
| Q3 24 | $2.1M | $12.9M | ||
| Q2 24 | $-1.4M | $10.0M |
| Q1 26 | — | $12.4M | ||
| Q4 25 | $3.9M | $43.2M | ||
| Q3 25 | $1.1M | $10.8M | ||
| Q2 25 | $902.7K | $12.8M | ||
| Q1 25 | $-3.7M | $8.3M | ||
| Q4 24 | $859.9K | $13.7M | ||
| Q3 24 | $2.0M | $7.0M | ||
| Q2 24 | $-1.5M | $2.7M |
| Q1 26 | — | 46.0% | ||
| Q4 25 | 14.0% | 178.3% | ||
| Q3 25 | 4.2% | 43.0% | ||
| Q2 25 | 3.5% | 53.6% | ||
| Q1 25 | -15.9% | 35.7% | ||
| Q4 24 | 3.3% | 65.6% | ||
| Q3 24 | 9.4% | 34.2% | ||
| Q2 24 | -7.3% | 14.0% |
| Q1 26 | — | 1.8% | ||
| Q4 25 | 0.3% | 13.7% | ||
| Q3 25 | 4.0% | 2.6% | ||
| Q2 25 | 6.8% | 3.2% | ||
| Q1 25 | 7.4% | 6.5% | ||
| Q4 24 | 0.3% | 125.3% | ||
| Q3 24 | 0.0% | 29.4% | ||
| Q2 24 | 0.3% | 37.1% |
| Q1 26 | — | 1.22× | ||
| Q4 25 | — | 6.26× | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | — | 1.70× | ||
| Q1 25 | — | 1.24× | ||
| Q4 24 | — | 5.61× | ||
| Q3 24 | — | 2.17× | ||
| Q2 24 | — | 1.93× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SMTI
| Soft Tissue Repair Products | $24.7M | 90% |
| Bone Fusion Products | $2.8M | 10% |
WTBA
Segment breakdown not available.
